Navigation Links
PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals

BOSTON, Nov. 23, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has appointed several executives to its global team of late phase and observational research experts in PAREXEL's PACE™ (Peri-Approval Clinical Excellence) group. This team will help sponsors collect the precise data they need to prove the value of their products to multiple stakeholders, and better position their products for commercial success.

"Observational research has become increasingly important as a means to demonstrate product value in a real world clinical setting," said Carol Collins, Ph.D., Corporate Vice President and Worldwide Head of PACE at PAREXEL.

"These appointments to the PAREXEL PACE global team of late phase experts add extensive expertise to help clients optimize the design and execution of their late phase and observational research programs to seamlessly move products from clinical development through commercialization."

The experts newly appointed to PAREXEL's PACE group include:

  • Peggy Schrammel, Vice President and Global Head Portfolio Management, PACE:  Ms. Schrammel's professional experience includes senior-level positions at major clinical research organizations (CROs), where she designed and managed late phase programs including patient registries, clinical-experience trials, pharmacoeconomic trials, and managed-care-based effectiveness trials. Ms. Schrammel received an undergraduate degree in political science and Master of Public Administration from the University of Pittsburgh.
  • Neal Mantick, Senior Director, Global Observational Research:  Mr. Mantick has over 25 years of experience in the pharmaceutical and biotech industries.  Prior to joining PAREXEL, he served as an Executive Director at Abt Bio-Pharma Solutions, Inc.where he led the Observational Studies/Registries Business Unit. Previously at Genzyme, he was responsible for ongoing management of four global registries for rare diseases. In that capacity, he participated in groundbreaking advancements in the medical treatment of patients and led the registry programs through growth and evolution to meet a wider range of clinical, regulatory, and commercial expectations. Mr. Mantick holds a B.S. degree in Pharmacy from the University of Kentucky and an M.S. degree in Health Policy and Management from the Harvard University School of Public Health.
  • David Brown, Ph.D., Vice President, Epidemiology:  Most recently, Dr. Brown served as Senior Director of Epidemiology at King Pharmaceuticals, which was acquired by Pfizer Inc. Prior to joining King Pharmaceuticals, he held senior positions in epidemiology and global safety surveillance, including serving as epidemiology team leader for oncology and neurosciences at Wyeth Research. Dr. Brown holds a doctorate in epidemiology from the University of Alabama at Birmingham, and earned his Master's degree in public health from Loma Linda University, as well as a Master's degree in cellular and molecular biology from the University of California at Riverside. 
  • Deborah Lubeck, Ph.D.,Vice President, Health Economics and Outcomes Research:  Prior to PAREXEL, Dr. Lubeck served as Vice President of Late Phase Services at a major CRO.  Previously, she was a member of the research faculty at Stanford University and the University of California, San Francisco. Dr. Lubeck has been involved in outcomes research for 25 years and has coauthored over 160 peer-reviewed publications. Her research has focused on the design and analysis of observational studies, including in the infectious disease, oncology, metabolism/endocrine and musculoskeletal therapeutic areas. 
  • PAREXEL's PACE™ team provides customized strategic and scientific solutions to facilitate the transition from product development to commercialization in a seamless and cost-effective manner. PAREXEL's late phase capabilities include Phase IIIb and IV clinical trials, observational research, post approval safety surveillance programs and case processing, and health economics and outcomes research services.  For more information, visit:

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 67 locations throughout 52 countries around the world, and has approximately 10,850 employees. For more information about PAREXEL International visit

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.
    For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated additional restructuring charges of approximately $4 million in the second quarter of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
    Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 as filed with the SEC on November 9, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts: Jennifer Baird, Senior Director of Public RelationsKim Leadley/Gene CarozzaPAREXEL International

    PAN CommunicationsTel: +781-434-4409

    Tel: + 617-502-4300Email:



    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
    2. UCB and PAREXEL Sign Strategic Partnership Agreement
    3. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
    4. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
    5. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
    6. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
    7. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
    8. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
    9. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
    10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
    11. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
    Post Your Comments:
    (Date:10/13/2015)... , Oct. 13 2015 ... addition of the "US & European ... Countries (2010-2021)" report to their offering. ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ...
    (Date:10/13/2015)... -- Graduate students across the country, with an interest ... have the opportunity to learn about a lesser-known ... and development process. Eli Lilly and Company (NYSE: ... from academic institutions to create an elective graduate ... Development."  Lilly will formally unveil the eLearning course ...
    (Date:10/13/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a ... serving the pharmaceutical, biotechnology, and medical device industries, ... version of OncoWuXi, the first App in the ... and data on the go.  The OncoWuXi App ... to identify relevant tumor models for use in ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... California (PRWEB) , ... October ... ... launched Postnatal Omega-3, a first-of-its kind product that targets the unique health ... Postnatal Omega-3” of the American Pregnancy Association ( ), utilizes Nordic ...
    (Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra Health ... 59,000 emergency department visits per year, today announced the successful and rapid deployment ... clinical, operational and financial outcomes. , In less than four days, ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe dentists’ office, ... IV sedation dentistry for more than 5 years. A leading cause of emergency ... painful if treatment is not timely. , Sedation dentistry provides an ...
    (Date:10/13/2015)... ... 2015 , ... World Patent Marketing , a vertically integrated manufacturer and ... helps people in clearing snow away from the streets and driveways. , "The Snowplowing ... year," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
    (Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN report published ... a teammate accidentally elbowed him in the left eye during the first day of ... one of a series of setbacks, including a knee injury that has interfered with ...
    Breaking Medicine News(10 mins):